SOCRA CCRP® Preparation Guide: Research Decisions from Start-Up to Closure Study Guide

Apply it

A physician proposes collecting extra blood samples at fixed intervals to test an unproven biomarker. Although patients already receive routine blood tests, the additional sampling serves a research question and needs review within the research plan.

Apply it

A supervisor wants to recruit laboratory employees into her study during performance reviews. The team instead uses an independent recruiter and private response process, explaining that participation decisions will not enter employment evaluations or affect workplace opportunities.

Apply it

A protocol includes a painful biopsy that does not contribute to its objectives or safety assessments. Removing that procedure reduces participant burden without weakening the research question, improving the ethical justification before the protocol reaches approval.

Apply it

A sponsor plans a general adult study but recruits only economically disadvantaged clinic patients because they are easy to contact. The team revises recruitment across suitable clinics and explains eligibility using scientific criteria rather than convenience alone.

Apply it

A study asks whether function improves after treatment, but its visit forms record only medication satisfaction. Before activation, the team aligns assessments and timing with the defined functional endpoint and trains staff on consistent measurement procedures.

Apply it

Clinicians prefer giving a new treatment to the healthiest participants. A concealed random allocation process prevents that preference from determining assignment, helping separate the treatment’s effect from baseline differences in prognosis between the resulting groups.

Apply it

Participants rate pain, and assessors discuss treatment experiences before recording scores. The team separates treatment management from outcome assessment and trains staff to avoid revealing assignments, reducing expectation-driven differences in how outcomes are reported and evaluated.

Apply it

Both study groups improve after enrollment, when all participants also receive structured supportive care. Comparing the groups estimates the additional effect of the investigational treatment more credibly than comparing each participant’s final result with their own baseline alone.

Apply it

A protocol excludes a particular medical condition but does not explain how recent its documentation must be. The site obtains clarification before screening begins and builds the required evidence and timing into its eligibility verification process.

Apply it

A trial’s primary endpoint depends on a tightly timed sample. During design, staff test transport arrangements and simplify scheduling so samples reach the laboratory within the required window, preventing a predictable threat to interpretable endpoint data.

Apply it

When reviewing a more-than-minimal-risk applicable clinical trial's draft, identify which procedures are experimental, check alternatives and injury arrangements, and confirm that confidentiality language explains possible FDA inspection. Include the required ClinicalTrials.gov statement, then separately assess each additional element under 50.25(b). Present all information in language understandable to the intended participants.

Apply it

A draft says participants accept all injury risks and cannot sue the institution. The reviewer removes that waiver, accurately describes injury-care arrangements, and ensures the form supplies usable contacts for study questions, participant rights, and research-related injuries.

Apply it

An adult with fluctuating cognition is considered for enrollment. The team assesses decision-making ability at the relevant time and verifies who may legally act if needed, rather than assuming an accompanying relative can automatically authorize participation.

Apply it

A minimal-risk project falls outside the published expedited categories. The investigator requests faster approval because enrollment is urgent, but urgency does not supply the missing category requirement; the appropriate review route must be established independently.

Apply it

A physician initiates and conducts an investigational drug study. Planning must address sponsor responsibilities as well as site conduct, rather than assuming that investigator qualifications, institutional permission, and a completed consent form cover the entire regulatory arrangement.

Apply it

A sponsor proposes nonsignificant risk, but the IRB determines the planned use presents significant risk. Enrollment cannot begin under the abbreviated route; the sponsor must address the FDA IDE pathway and the required notification of the disagreement.

Apply it

A site has sponsor permission to open, but its IRB approval covers an earlier consent version. Before recruiting under the revised materials, staff resolve the approval mismatch and verify that all remaining activation conditions have been satisfied.

Apply it

A new Investigator’s Brochure adds an important risk. The site preserves the previous edition, records receipt and review of the update, and evaluates consequences for staff training, participant communication, and the documents submitted to the reviewing IRB.

Apply it

A sponsor pays an investigator's institution $40,000 solely for documented costs of conducting the covered study. That payment does not itself trigger significant-payments-of-other-sorts disclosure. The sponsor also pays the investigator $30,000 for unrelated consulting during the study; those consulting payments exceed the $25,000 threshold and require disclosure. Sponsor shares worth $55,000 held by the investigator's spouse also require evaluation and disclosure under the equity criterion.

Apply it

A clinic sees many patients with the target disease but lacks staff for weekend safety assessments. The sponsor evaluates staffing and coverage before selection instead of accepting a large enrollment forecast that cannot be supported by protocol-compliant operations.

Apply it

A coordinator is skilled at scheduling but has no qualification to interpret clinical safety findings. The investigator delegates appointment management while assigning safety interpretation to a qualified clinician and establishes how urgent results will reach that clinician.

Apply it

A replacement nurse has current GCP training but has never handled the study’s timed sample processing. Before independent work, the site provides procedure-specific instruction, observes performance, and documents readiness and the escalation route for processing problems.

Apply it

A validated platform is configured with a new eligibility calculation. The team verifies the study-specific formula and boundary values before use, because the vendor’s general platform testing does not establish that this configuration correctly determines enrollment eligibility.

Apply it

Before first enrollment, the sponsor assigns ClinicalTrials.gov responsibilities and tracks the 21-calendar-day registration clock. When primary-outcome collection finishes, the team records the primary completion date and schedules results preparation against the general one-year deadline. If seeking a permitted delay, the responsible party follows the applicable certification or extension procedure rather than simply postponing submission.

Apply it

A participant signs quickly but says the investigational treatment is guaranteed to work. Staff pause enrollment, explain uncertainty and alternatives in understandable language, check understanding again, and complete consent before any research-specific blood collection or intervention begins.

Apply it

An advertisement promises a proven cure from an investigational device. The site stops using it, revises the benefit claim to reflect uncertainty, and obtains appropriate IRB review of the recruitment material before resuming its use with prospective participants.

Apply it

A screening result falls outside an inclusion range. Staff verify units and the original report, then apply the protocol’s permitted retesting rules if any; they do not round the value into range or treat a sponsor’s recruitment target as authorization.

Apply it

A sponsor sends a revised visit schedule that reduces several assessments. Because no immediate hazard exists, the site continues the approved schedule while obtaining required approval and preparing updated scheduling tools and staff instructions for the authorized transition.

Apply it

A newly recognized procedural danger requires stopping the implicated procedure immediately. The investigator protects participants, documents the hazard and protective action, and promptly informs the sponsor and IRB through the required pathway rather than waiting for routine amendment review.

Apply it

A newly identified risk applies to participants still receiving treatment. The investigator arranges timely discussion, coordinates revised materials with the IRB, and documents participants’ decisions about continuing, rather than waiting until their next distant routine study visit.

Apply it

A participant signs a research consent form, but the proposed hospital-record disclosure is not covered by a valid HIPAA authorization. The team establishes the appropriate authorization or permitted alternative before the covered entity releases information for that research use.

Apply it

A records study needs identifiable historical data and cannot practicably obtain individual authorizations. Investigators explain both impracticability findings and provide identifier-protection, destruction, and disclosure controls for review, rather than relying solely on the project’s minimal physical risk.

Apply it

A coordinator proposes sharing one account with temporary staff to speed data entry. The site instead assigns individual accounts with suitable permissions, protects the identifying code list, and removes access when staff no longer need study-system privileges.

Apply it

A refrigerator alarm shows an overnight excursion affecting investigational kits. Staff segregate the kits from usable stock, preserve temperature records, notify the responsible parties, and await documented disposition instructions before dispensing any affected supply to study participants.

Apply it

A pharmacy receives 150 sealed kits, dispenses 90, and has no returns, transfers, or destruction. Sixty kits should remain. A physical count of 58 prompts review of dispensing records and stock movements rather than an unsupported inventory adjustment.

Apply it

A sponsor identifies a problem with a particular investigational-device batch. The site uses its receipt and participant-exposure records to locate unused units and identify affected participants for appropriate assessment, rather than relying on aggregate inventory totals alone.

Apply it

A participant develops an infection during treatment, but its cause remains uncertain. Staff document the event and arrange assessment of seriousness, expectedness, and relationship; they do not omit it merely because the investigator has not established that the product caused it.

Apply it

A participant reports an intensely painful headache without hospitalization or another seriousness criterion. Another experiences a modest symptom requiring inpatient admission. The team assesses severity and seriousness separately rather than classifying both events solely by symptom intensity.

Apply it

Reference information describes mild liver-enzyme elevations, but a participant develops severe liver failure. The assessor compares the actual reaction with the documented nature and severity of the listed risk rather than labeling it expected simply because both involve the liver.

Apply it

A participant is hospitalized overnight, and the discharge summary is unavailable. The coordinator alerts the investigator and sponsor with known facts through the study’s urgent process, then obtains records and submits follow-up rather than waiting for a complete narrative.

Apply it

A sponsor determines that a nonfatal event is a serious, unexpected suspected adverse reaction qualifying for IND reporting. It initiates the report promptly using the determination date for the applicable maximum period, while continuing to investigate missing follow-up details.

Apply it

A sponsor first receives adequate information describing an unexpected fatal suspected adverse reaction on Monday. It begins expedited FDA notification immediately, tracks the maximum period from initial receipt, and actively obtains additional records rather than restarting the clock after internal review.

Apply it

An IDE investigator learns of a device-associated serious effect meeting the unanticipated-effect definition. The site begins sponsor and IRB reporting promptly, records when the investigator first learned of it, and supplements the initial report as relevant details become available.

Apply it

Several participants miss a required safety assessment because reminders use the wrong visit schedule. The site documents each occurrence, evaluates any clinical consequences, informs the appropriate parties, and investigates the scheduling process rather than treating the events as unrelated participant failures.

Apply it

A participant declines further study medication because of travel burden but is willing to answer safety calls. The team documents treatment discontinuation and the agreed follow-up, arranging appropriate care rather than coding the person as completely lost to follow-up.

Apply it

Participants experiencing troublesome symptoms stop attending visits more often in one treatment group. The team investigates the pattern and offers permitted follow-up options, recognizing that analysis of completers alone may understate the intervention’s harms and misrepresent its overall effects.

Apply it

A nurse copies a laboratory result from the original laboratory report into the electronic case report form. The report remains the source, and the nurse is the originator of the transcribed data element; both relationships must remain traceable.

Apply it

A coordinator notices a transposed laboratory value in the electronic case report form. After checking the original report, the authorized coordinator corrects the field and records the transcription-error reason while the system retains the old value, identity, and correction time.

Apply it

A query flags an unusually high measurement that matches the contemporaneous source record. The site confirms the value and provides appropriate clarification instead of changing it to a typical number solely to satisfy the database’s edit check.

Apply it

A vendor plans to close the site’s portal immediately after database lock. Before access ends, the investigator confirms the required records and metadata are preserved in an accessible, trustworthy form and that review and retention responsibilities remain achievable.

Apply it

A scale used for eligibility assessments fails its scheduled accuracy check. The site removes it from use, reviews the interval since reliable performance was last established, and evaluates affected assessments before deciding whether reassessment or other action is needed.

Apply it

Repeated consent-version errors arise because obsolete forms remain in a shared folder. The site controls document access, removes superseded working copies, updates release procedures, and checks subsequent enrollments for correct-version use instead of relying solely on another training presentation.

Apply it

Central review identifies one site with increasingly delayed safety entries and missing endpoint assessments. The sponsor investigates staffing and workflow, increases targeted oversight as appropriate, and evaluates whether a site visit and corrective measures are needed to address the pattern.

Apply it

At inspection close, a site receives observations about inadequate records. The investigator reviews the facts, preserves supporting evidence, and prepares a specific corrective response, while recognizing that the Form 483 itself does not constitute FDA’s final enforcement decision.

Apply it

A site’s final visit is complete, but several safety follow-ups and product discrepancies remain. The closeout review assigns owners and follow-up arrangements, ensuring the issues stay visible and are resolved before responsibilities and access arrangements are wound down.

Apply it

A site closes with unopened investigational-drug kits. Staff compare physical stock with accountability records, resolve differences, and follow authorized return instructions, retaining shipment and reconciliation evidence rather than discarding the kits through the clinic’s usual medication-waste service.

Apply it

A site completes its portion of a significant-risk IDE investigation while other sites continue. The investigator prepares the final report for the sponsor and reviewing IRB within three months of site completion rather than waiting for global completion. For an abbreviated nonsignificant-risk study, the team instead identifies the incorporated federal duties and any separate IRB or protocol requirements.

Apply it

A sponsor stops a study early after a safety concern. The investigator promptly contacts affected participants, explains the implications, arranges appropriate medical review and follow-up, and coordinates required notifications rather than simply canceling future visits and archiving the records.

Apply it

A site closed three years ago, but the investigated indication received marketing approval only six months ago. The IND retention endpoint has not arrived; the site preserves records and checks other applicable obligations rather than counting solely from its closeout date.

Apply it

A site replaces its electronic platform after closeout. Before retirement, it verifies that retained records, signatures, and relevant audit histories remain readable and linked, identifies a custodian, and tests retrieval using the planned archive arrangements and access procedures.